Loading
Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide.
Beijing Pearl Biotechnology Limited Liability Company appears on ClinicalTrials.gov as the industry sponsor of 3 interventional cancer trials (phase 2/3, 3), testing PLB1001, Temozolomide in glioblastoma, non-small cell lung cancer, non-small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.